Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-07-17
2007-07-17
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S105000
Reexamination Certificate
active
10504109
ABSTRACT:
Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed:wherein A is optionally substituted phenyl, naphthyl, indolyl, quinolinyl, quinazolinyl, indazolyl, isoquinolinyl or benzofuranyl; b is 1, 2 or 3 and c is 1, 2 or 3, wherein b+c is 2, 3, 4 or 5; X is carbon, Y is CH,is a double bond and e is 0; or X is carbon, Y is CH2or oxygen,is a single bond and e is 1; or X is nitrogen, Y is CH2,is a single bond and e is 0; R1 is hydrogen, cyano, halogen, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, NHCOCH3or OCONR5R6, wherein R5 and R6 are independently hydrogen or C1-6alkyl; R2 is halogen, cyano or C1-6alkoxy; d is 0, 1, 2 or 3; R3 is hydrogen, C1-6alkyl, C1-6alkanoyl, fluoroC1-6alkanoyl, C1-6alkylsulfonyl, fluoroC1-6alkylsulfonyl, carbamoyl, C1-6alkylcarbamoyl or arylC1-6alkyl; and R4, together with the nitrogen atom to which it is attached, forms an optionally substituted 5 to 7 membered heterocyclic group fused to the benzene ring, provided that when a compound of formula (I) has the following structure:wherein A, b, c, R1, e, X, Y, R2 and d are as defined above and R3 is hydrogen, C1-6alkyl or arylC1-6alkyl, then (i) X is carbon, Y is CH andis a double bond; or (ii) b and c are both 1; or (iii) the carbon atom adjacent to the oxo-substituted carbon atom in the morpholinyl ring, marked “★”, is substituted. Methods of preparing the compounds and uses of the compounds in therapy, in particular for a CNS disorder such as depression or anxiety, are also disclosed.
REFERENCES:
patent: 0 900 792 (1999-03-01), None
patent: WO 95 28400 (1995-10-01), None
patent: WO 97 45419 (1997-12-01), None
patent: WO 99 51592 (1999-10-01), None
patent: WO 00 40581 (2000-07-01), None
patent: WO 02 34754 (2002-05-01), None
Harrington Frank P
Smith Paul W
Ward Simon E
Glaxo Group Limited
Habte Kahsay
Kinzig Charles M.
McCarthy Mary E.
Sieburth Kathryn L.
LandOfFree
Heterocyclic compounds possessing affinity at 5HT 1 -type... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds possessing affinity at 5HT 1 -type..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds possessing affinity at 5HT 1 -type... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3818035